Research Analysts Set Expectations for HRMY FY2026 Earnings

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) – Equities research analysts at Cantor Fitzgerald issued their FY2026 earnings per share (EPS) estimates for shares of Harmony Biosciences in a note issued to investors on Monday, June 9th. Cantor Fitzgerald analyst P. Stavropoulos expects that the company will earn $3.21 per share for the year. Cantor Fitzgerald has a “Strong-Buy” rating on the stock. The consensus estimate for Harmony Biosciences’ current full-year earnings is $2.43 per share.

Harmony Biosciences (NASDAQ:HRMY) last issued its earnings results on Tuesday, May 6th. The company reported $0.78 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.59 by $0.19. Harmony Biosciences had a return on equity of 23.16% and a net margin of 17.98%. The business had revenue of $184.73 million during the quarter, compared to analysts’ expectations of $184.26 million. During the same period in the prior year, the firm posted $0.67 EPS. Harmony Biosciences’s quarterly revenue was up 19.5% compared to the same quarter last year.

HRMY has been the subject of a number of other reports. UBS Group dropped their price target on Harmony Biosciences from $55.00 to $48.00 and set a “buy” rating for the company in a report on Monday, April 28th. Needham & Company LLC reaffirmed a “buy” rating and set a $49.00 price target on shares of Harmony Biosciences in a report on Tuesday, May 6th. HC Wainwright reaffirmed a “buy” rating and set a $70.00 price target on shares of Harmony Biosciences in a report on Tuesday, April 8th. Mizuho raised their price target on Harmony Biosciences from $44.00 to $48.00 and gave the company an “outperform” rating in a report on Thursday, May 15th. Finally, Oppenheimer began coverage on Harmony Biosciences in a research report on Monday, June 2nd. They issued an “outperform” rating and a $61.00 price objective on the stock. Eight analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $53.00.

Harmony Biosciences Trading Down 5.2%

HRMY stock opened at $33.33 on Wednesday. The business has a fifty day moving average price of $32.14 and a 200 day moving average price of $34.09. Harmony Biosciences has a fifty-two week low of $26.47 and a fifty-two week high of $41.61. The stock has a market capitalization of $1.91 billion, a price-to-earnings ratio of 15.80, a P/E/G ratio of 0.47 and a beta of 0.87. The company has a debt-to-equity ratio of 0.28, a current ratio of 3.24 and a quick ratio of 3.20.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Financial Management Professionals Inc. bought a new position in shares of Harmony Biosciences in the 1st quarter worth $29,000. Brooklyn Investment Group boosted its position in shares of Harmony Biosciences by 1,031.9% in the 1st quarter. Brooklyn Investment Group now owns 1,064 shares of the company’s stock worth $35,000 after purchasing an additional 970 shares during the last quarter. GF Fund Management CO. LTD. bought a new position in shares of Harmony Biosciences in the 4th quarter worth $41,000. Caitong International Asset Management Co. Ltd bought a new position in shares of Harmony Biosciences in the 1st quarter worth $57,000. Finally, KBC Group NV boosted its position in shares of Harmony Biosciences by 79.9% in the 4th quarter. KBC Group NV now owns 1,844 shares of the company’s stock worth $63,000 after purchasing an additional 819 shares during the last quarter. 86.23% of the stock is currently owned by institutional investors.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.